Afrin Extra nasal spray for rhinitis with eucalyptus and menthol , 15 ml., Bayer
Category
Runny nose
Scope of the medicinal product
Ear, Throat, Nose
Release form
Spray
Manufacturer country
Canada
Package quantity, pcs
one
Release form, composition and packaging
?
Nasal spray 0.05% in the form of a gel-like suspension of white or almost white color, with a characteristic odor.
1 ml
oxymetazoline hydrochloride 500 mcg
microcrystalline cellulose and sodium carmellose (avicel RC-591) - 30 mg, sodium hydrogen phosphate - 975 μg, sodium dihydrogen phosphate monohydrate - 5.525 mg, disodium edetate dihydrate - 300 μg, macrogol 1450 - 50 mg, povidone K29-32 - 30 mg, benzyl alcohol - 3 mg, cineole - 200 μg, camphor - 200 μg, levomenthol - 600 μg, benzalkonium chloride solution 17% - 1.471 mg, polypropylene glycol - 5 mg, purified water - qs up to 1 ml.
15 ml - plastic bottles with a dosing device (1) - cardboard packs.
pharmachologic effect
Adrenomimetic agent for topical use.
Has a vasoconstrictor effect.
With intranasal administration, the swelling of the mucous membrane of the upper respiratory tract decreases.
When instilled into the conjunctival sac, it reduces the swelling of the conjunctiva.
Pharmacokinetics
The effect is manifested 15 minutes after application and lasts for 6-8 hours.
Indications for use
Difficulty in nasal breathing with colds, sinus inflammation, eustachitis, hay fever, allergic rhinitis, congestion and edema of the conjunctiva.
Contraindications for use
Inflammation of the nasal mucosa without secretion, chronic heart failure, hyperthyroidism, diabetes mellitus, pregnancy, children under 6 years of age (for eye drops), hypersensitivity to oxymetazoline, atrophic rhinitis, lactation period, arrhythmias, severe atherosclerosis, arterial hypertension, chronic renal failure , angle-closure glaucoma.
Dosage regimen
Apply topically.
Side effect
From the respiratory system: transient dryness and burning of the nasal mucosa, dry mouth and throat, sneezing are possible
with prolonged use, the appearance of reactive hyperemia of the mucous membrane, atrophy of the mucous membrane is possible.
On the part of the cardiovascular system: palpitations
rarely - arterial hypertension.
From the side of the central nervous system: increased excitability, dizziness, headache, sleep disturbances
with prolonged use - tachyphylaxis.
From the digestive system: nausea.
From the side of the organ of vision: with conjunctival administration, mydriasis, paresis of accommodation, irritation of the conjunctiva and surrounding tissues, eyelid retraction are possible.
Drug interactions
With the simultaneous appointment of MAO inhibitors and tricyclic antidepressants, an increase in blood pressure is possible.
Oxymetazoline slows down the absorption of local anesthetic drugs, lengthens their effect.
The co-administration of other vasoconstrictor drugs increases the risk of side effects.
Application during pregnancy and lactation
Oxymetazoline is contraindicated during pregnancy and lactation (breastfeeding).
Special instructions In the recommended dosage without consulting a doctor, you can use no more than 3 days.
Avoid getting the drug intended for intranasal administration in the eyes.
Influence on the ability to drive vehicles and control mechanisms The drug affects vision, a decrease in the reaction rate is possible.
Name ENG
AFRIN EXTRO
Clinical and pharmacological group
A vasoconstrictor drug for local use in ENT practice
ATX code
Oxymetazoline
Dosage
0.05% x 15ml
Structure
Active ingredient: oxymetazoline hydrochloride 0.5 mg
Excipients: disodium edetate dihydrate - 300 μg, sodium hydrogen phosphate - 975 μg, sodium dihydrogen phosphate monohydrate - 5.525 mg, povidone K29-32 - 30 mg, benzalkonium chloride solution 17% - 1.471 mg, macrogol 1450 - 50 mg, benzyl alcohol - 2.5 mg, microcrystalline cellulose and sodium carmellose (Avicel RC-591) - 30 mg, lemon flavoring - 1.5 mg, purified water - qs up to 1 ml.
INN / Active ingredient
Oxymetazoline
Storage conditions and periods
At a temperature not higher than 25 degrees.
Expiration date: 2 years
Specifications
Category
Runny nose
Scope of the medicinal product
Ear, Throat, Nose
Release form
Spray
Manufacturer country
Canada
Package quantity, pcs
one
Scope of application
Virology
Minimum age from
6 years
Way of introduction
Through the respiratory tract
Vacation conditions
Without recipe
Volume, ml.
15 ml
Brand name
Afrin
The amount of the dosage form in the primary package
15 ml
Primary packaging type
Bottle
Type of consumer packaging
Pack of cardboard
Pharmaco-therapeutic group
Decongestant - alpha adrenergic agonist
Anatomical and therapeutic characteristics
R01AA05 Oxymetazoline
Dosage form
Nasal spray
Expiration date in days
730
The target audience
Children
Package weight, g
twenty
Mode of application
:
Shake the bottle vigorously before each use.
Before using the nasal spray for the first time, it must be calibrated" by pressing the spray head several times.
Adults and children over 6 years old - 2-3 injections into each nasal passage with an interval of 10-12 hours. In adults, the frequency of application can be increased up to 3 times a day in adults.
It is not recommended to exceed the indicated dose.
Information on technical characteristics, delivery set, country of manufacture "